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CCL21 Protein Leads to Advancements in Understanding Lung Transplant Rejection
Cecilie Elliott

Department of Biological and Environmental Sciences

BACKGROUND

SPECIFIC AIM
The specific aim of this study targets to reduce the rejection in post lung transplant
subjects by increasing the amount of CCL21 by injecting the DC/CCL21 vaccination
to express T and B cells more efficiently.4

POTENTIAL PITFALLS
•
•
•
•
•
Figure 1. Comparison of a normal/healthy lung versus a degraded lung with IPF.3

Small sample size of mice
Death of mice during experiment
No progression of IPF in mice to determine if worthy of transplant
Vaccine does not reduce rejection after transplant
Mice getting fungal or viral infections, in which the vaccine targets bacterial
infections

Figure 3. Comparison of the different types of infection post transplant in 3 different areas of
the body. 1

Figure 2. CCL21 expression is improved in mice post-DC/CCL21 vaccination.
Immunofluorescence staining of LNs and spleen was performed on day 50 after transplant to
assess for CCL21 (blue), B cells (B220) (green) and T cells (CD8a)(red).5

•
•
•
•

Chemokines are a part of the innate and adaptive immune system which can
help fight inflammation in the body.6
CCL21 is expressed in the lymph nodes to help guide naïve T cells and can be
beneficial when treating patients with transplant rejection, as well as, help
with immunologic tolerance.2
TNF- α is part of the signaling pathway to bring in other proteins to fight
infections/inflammation.4
IL-4 is secreted during an anti-inflammatory response to help activate B cells
and control T cell proliferation.6

POTENTIAL CONCLUSIONS
•
•
•
•

DC/CCL21 inhibits CCL21 to decrease the number of deaths world-wide postlung transplant
Overtime, there would be higher survival rates
More data to help prevent chronic rejection in lung transplant recipients
Possible leads to curing particular uncured lung diseases like IPF to one day
lowering the number of patients on the transplant list

METHODS
45 C57BL/6 mice
are injected with
and IPF cell line

Bioilluminescence
imaging of IPF
progression

Group Xa
-DC/CCL21 vaccine administered
Group Xb
-DC/null vaccine administered
Group Y (Control)

Transplant process
according to group

-No lung transplant or vaccine administered

Immunofluorescence staining of LN and
lung tissue observing CCL21, T cells
(CD8a), and B cells (B220)

Kaplan-Meir survival analysis across all
groups

One-way ANOVA with a post-hoc Turkey
test and Student's t test unpaired
comparison to determine significance
between each group
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